Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Scipibaimab Combined With Tislelizumab in Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT07388758Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Feb 2026
- Primary completion
- Feb 2028
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of lunsekimig in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
lunsekimig
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07388758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07388758.